Fibrin sealant patch - Takeda
Alternative Names: Absorbable fibrin sealant patch; Fibrin-sealant; Medicated sponge - Nycomed; TachoComb; TachoSilLatest Information Update: 24 Apr 2023
At a glance
- Originator Nycomed
- Developer Corza Health; Takeda Pharmaceuticals International GmbH
- Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
- Mechanism of Action Fibrinogen replacements; Thrombin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Surgical blood loss
Most Recent Events
- 20 Apr 2023 Preregistration for Surgical blood loss (In children, In infants, In adolescents) in USA (Topical)
- 20 Apr 2023 Fibrin sealant patch receives a positive Opinion from EMA for use in pediatric patients in Europe
- 02 Feb 2021 Corza Health acquires assets and licenses for the development and commercialization of fibrin sealant patch (TachoSil®)from Takeda